Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer?

World Journal of Gastroenterology

Volumn 13, Issue 32, 2007, Pages 4306-4309

  Ishikawa, Toru ^a  

^a Saiseikai Niigata Second Hospital   (Japan)

Author keywords

Intra arterial chemotherapy; Pancreatic cancer; Systemic chemotherapy

Indexed keywords

ANGIOTENSIN II; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GEMCITABINE; GLYCOPROTEIN P; MITOMYCIN C; MITOXANTRONE; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG TISSUE LEVEL; EDITORIAL; FIRST PASS EFFECT; HEMODYNAMICS; HUMAN; MONOTHERAPY; PANCREAS CANCER; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRA-ARTERIAL; PANCREATIC NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 34548511071     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i32.4306     Document Type: Editorial

References (44)

1. Gold EB, Cameron JL. Chronic pancreatitis and pancreatic cancer. N Engl J Med 1993; 328: 1485-1486
2. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-124; discussion 124-125
3. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994; 81: 102-107
4. Connolly MM, Dawson PJ, Michelassi F, Moossa AR, Lowenstein F. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206:366,373
5. Carter SK, Corrds RL. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2: 193-214
6. Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer 1981; 47: 1724-1728
7. Douglass HO. Current approaches to multimodality management of advanced pancreatic cancer. Hepatogastroenterology 1993; 40: 433-442
8. Nicolson M, Webb A, Cunningham D, Norman A, O'Brien M, Hill A, Hickish T. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 1995; 6: 801-804
9. Evans TR, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG, Knight MJ. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996; 73: 1260-1264
10. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 1996; 78: 633-638
11. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RY, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-353
12. Fung MC, Sakata T. What's new in pancreatic cancer treatment? J Hepatobiliary Pancreat Surg 2002; 9: 61-75
13. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
14. Bosch X. Fluorouracil and mitomycin for pancreatic cancer. Lancet Oncol 2005; 6: 644
15. Whitehouse PA, Cooper AJ, Johnson CD. Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines. Pancreatology 2003; 3: 367-373; discussion 373-374
16. Ashraf S, Loizidou M, Crowe R, Turmaine M, Taylor I, Burnstock G. Blood vessels in liver metastases from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells. Clin Exp Metastasis 1997; 15: 484-498
17. Peterson HI, Mattson J. Vasoactive drugs and tumor blood flow. Biorheology 1984; 21: 503-508
18. Mattson J, Appelgre. L, Karlsson L, Peterson HI. Influence of vasoactive drugs and ischaemia on intra-tumour blood flow distribution. Eur J Cancer 1978; 14: 761-764
19. Sasaki Y, Imaoka S, Hasegawa Y, Nakano S, Ishikawa O, Ohigashi H, Taniguchi K, Koyama H, Iwanaga T, Terasawa T. Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. Cancer 1985; 55: 311-316
20. Ishikawa T, Mizuno K, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kairdmura T. A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy. Gan To Kagaku Ryaho 2005; 32: 523-527
21. Ishikawa T, Mizuno K, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination. Gan To Kagaku Ryoho 2005; 32: 469-472
22. Ishikawa T, Mizuno K, Watanabe K, Baba Y, Oota H, Yoshida T, Kamimura T. A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/ uracil. Gan To Kagaku Ryoho 2004; 31: 1555-1558
23. Ishikawa T, Nomura K, Baba Y, Hayashi S, Oota H, Yoshida T, Kamimura T. A case of advanced gastric cancer with liver and intra-abdominal lymph node inetastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy. Gan To Kagaku Ryoho 2003; 30: 1151-1155
24. Ishikawa T, Mita Y, Kobayashi M, Tashiro K, Tashiro S, Matsuki H, A case of nonresectable scirrhous type gastric cancer treated by hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy. Gan To Kagaku Ryoho 2001; 28: 1137-1140
25. Ishikawa T, Sato S, Matsuzawa J, Mita Y, Matsui S, Tashiro K, Tashiro S, Matsuki H. A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with angiotensin-II and administration of tegafur/uracil. Gan To Kagaku Ryoho 2001; 28: 521-525
26. Ishikawa T, Ushiki T, Kamimura H, Togashi T, Tsuchiya A, Watanabe K, Seki K, Ohta H, Yoshida T, Takeda K, Kamimura T. Angiotensin-II administration is useful for the detection of liver metastasis from pancreatic cancer during pharmacoangiographic computed tomography. World J Gastroenterol 2007; 13: 3080-3083
27. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC, Gallot D. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10: 1112-1118
28. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 32A: 1039-1050
29. Muchmore JH, Preslan JE, George WJ. Regional chemotherapy for inoperable pancreatic carcinoma. Cancer 1996; 78: 664-673
30. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Cxist W, Brodeur GM. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124
31. Muchmore JH, Preslan JE, George WJ. Regional chemotherapy for inoperable pancreatic carcinoma. Cancer 1996; 78: 664-673
32. Theodors A, Bukowski RM, Hewlett JS, Livingston RB, Weick JK. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. Am J Clin Oncol 1982; 5: 555-558
33. Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, Nakamori S, Hiratsuka M, Imaoka S. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994; 168: 361-364
34. Ishikawa O, Ohigashi H, Sasaki Y, Masao K, Kabuto T, Furukawa H, Imaoka S. Adjuvant therapies in extended pancreatectomy for ductal adenocarcinoma of the pancreas. Hepatogastroenterology 1998; 45: 644-650
35. Beger HG, Link KH, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study. Hepatogastroenterology 1998; 45: 638-643
36. Beger HG, Gansauge F, Buchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg 1999; 23: 946-949
37. Mambrini A, Sanguinetti F, Pacetti P, Caudana R, Iacono C, Guglielmi A, Guadagni S, Del Freo A, Fiorentini G, Cantore M. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo 2006; 20: 751-755
38. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214
39. Maurer CA, Borner MM, Lauffer J, Friess H, Z'graggen K, Triller J, Buchler MW. Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. Int J Pancreatol 1998; 23: 181-186
40. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000; 89: 303-313
41. Cantore M, Pederzoli P, Cornalba G, Fiorentini G, Guadagni S, Miserocchi L, Frassoldati A, Ceravolo C, Smerieri F, Muchmore JH. Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000; 11: 569-573
42. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG. Regional chemotherapy in advanced pancreatic carcinoma. Med Min (Munich) 1995; 90: 501-505
43. Lorenz M, Heinrich S. Regional chemotherapy. Hematol Oncol Clin North Am 2002; 16: 199-215
44. Ishikawa T, Kamirnura H, Tsuchiya A, Togashi T, Watanabe K, Seki K Ohta H, Yoshida T, Takeda K, Kamimura T. Clinical Efficacy of Intra-arterial Pharmacokinetic Chemotherapy with 5-Fluorouracil, CDDP, Gemcitabine, and Angiotensin-II in Patients with Advanced Pancreatic Cancer. Hepato-Gastroenterology 2007; in press